Search results
Showing 8461 to 8475 of 8916 results
This guidance has been updated and replaced by NICE guideline NG92.
This guideline has been updated and replaced by NICE guideline NG247.
Smoking: preventing uptake in children and young people (PH14)
This guideline has been updated and replaced by the NICE guideline on tobacco: preventing uptake, promoting quitting and treating dependence (NG209).
This guidance has been updated and replaced by NICE guideline NG60.
HIV testing: increasing uptake in men who have sex with men (PH34)
This guideline has been updated and replaced by NICE guideline NG60.
Tuberculosis: identification and management in under-served groups (PH37)
This guideline has been updated and replaced by NICE guideline NG33.
This guideline has been updated and replaced by the NICE guideline on tobacco: preventing uptake, promoting quitting and treating dependence (NG209).
Substance misuse interventions for vulnerable under 25s (PH4)
This guidance has been updated and replaced by NICE guideline NG64.
Weight management: lifestyle services for overweight or obese adults (PH53)
This guideline has been updated and replaced by NICE guideline NG246.
This guideline has been updated and replaced by NICE guideline NG135.
This guideline has been updated and replaced by NICE guideline NG90.
This guidance has been updated and replaced by NICE guideline NG44.
This guideline has been updated and replaced by the NICE guideline on tobacco: preventing uptake, promoting quitting and treating dependence (NG209).
This advice has been updated and replaced by NICE medical technologies guidance 42.
Absorb Bioresorbable Vascular Scaffold system for coronary artery disease (MIB84)
NICE withdrew this medtech innovation briefing in November 2017 after the company stopped manufacturing Absorb because of low uptake. Some UK hospitals continue to use the technology in ongoing clinical studies.